First AD

Second AD

Clinical Trials and Real-World Data on Brexu-Cel

Video content above is prompted by the following:

Aside from obe-cel’s different design, what are the differences between the dosing and lymphodepletion regimen among brexu-cel, tisa-cel, and obe-cel?

Please comment on obe-cel’s double infusion approach.

Please review the ZUMA-3 trial study design and key data updates with brexu-cel.

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

ASH 2024: Breakthrough Insights on CAR T-Cell Therapy for Relapsed/Refractory ALL 

Peer Exchange

Panelists discuss how the dosing and lymphodepletion regimens of  brexucabtagene autoleucel (brexu-cel),  tisagenlecleucel (tisa-cel), and obecabtagene autoleucel (obe-cel) differ, with insights into obe-cel’s double infusion approach, as well as a deeper dive into the ZUMA-3 trial’s design and data updates with brexu-cel in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).